Project: A novel topical therapy for Atopic Dermatitis through development of LXR agonists

This project will deliver a novel topical therapy for Atopic Dermatitis (AD). AD is a common, chronic, inflammatory skin disease. A great body of evidence supports Liver X Receptors (LXRs) as a therapeutic target for AD. The DERMAL project will perform lead selection and preclinical development based on a newly identified chemical series of LXR agonists. This project will produce formulated lead compounds that will be ready for clinical trials within 18 months after completion of this project.

Acronym DERMAL (Reference Number: 10449)
Duration 01/10/2016 - 01/10/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner